DGNOF - DIAGNOS Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.1646
0.0000 (0.00%)
At close: 3:58PM EDT
Stock chart is not supported by your current browser
Previous Close0.1646
Open0.1660
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1646 - 0.1646
52 Week Range0.0300 - 0.6000
Volume11,000
Avg. Volume834
Market Cap6.528M
Beta (3Y Monthly)2.61
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire

    DIAGNOS Announces an Extension to the Diabetic Retinopathy Screening Services Assisted by Artificial Intelligence (AI) at the CHUM

    Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK) (DGNOF) a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today the extension of its technological showcase for the automated detection of Diabetic Retinopathy at the CHUM (Centre Hospitalier de l’Université de Montréal) until the end of August 2019. Launched in June 2018 in collaboration with the ophthalmology and endocrinology department, the technology showcase has so far allowed several hundred diabetic patients from the CHUM to access screening technology.

  • GlobeNewswire

    DIAGNOS Welcomes Mr. François Côté to its Board of Directors

    Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK) (DGNOF) a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), is pleased to announce the appointment of Mr. François Côté to its board of directors. Mr. Côté is currently Vice Chair of the TELUS Fund, an independent organization established to promote health and individual wellness.

  • GlobeNewswire

    DIAGNOS Announces Short Term Financing

    BROSSARD, Quebec, June 17, 2019 -- Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK) (OTCQB:DGNOF) a leader in early detection of critical health issues through.

  • GlobeNewswire

    DIAGNOS Announces Corporate Reorganization Update

    DIAGNOS Inc. (“DIAGNOS”, “the Corporation” or “we””) (TSX Venture: ADK), (DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces that it has completed the reorganization of its debt and capital structure initially announced on March 11, 2019. As announced on May 15, 2019, DIAGNOS proceeded with the redemption of 100% of the principal amount of the Debentures and the unpaid and accrued interest up to May 14, 2019. As announced on May 15, 2019, DIAGNOS proceeded with the redemption of 85% of the principal amount of the Notes and the unpaid and accrued interest up to May 14, 2019.

  • GlobeNewswire

    DIAGNOS Announces HIPAA Compliance for the US market

    DIAGNOS Inc. (“DIAGNOS”, “the Corporation” or “we”) (TSX Venture: ADK) (DGNOD), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today that its quality management system now fully complies with the requirements of the Health Insurance Portability and Accountability Act (“HIPAA”). HIPAA sets the standard for sensitive patient data protection. DIAGNOS has put in place the necessary physical network, and process security measures to ensure HIPAA Compliance.

  • GlobeNewswire

    DIAGNOS Announces the Appointment of Mr. Riadh Kobbi as Vice President Business Intelligence

    Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK), (DGNOD), a leader in early detection of critical health issues through the use of Artificial Intelligence (AI), announces today the appointment of Riadh Kobbi as Vice President Business Intelligence. Riadh has more than 20 years of international experience in the statistics field applied to computer software, having occupied executive roles in companies located in France, Turkey, Morocco and Cyprus. Riadh is one the first graduates of the master program in Business Intelligence at HEC Montreal.

  • GlobeNewswire

    DIAGNOS Adds a Second Screening Site at the CHUM in the Ophthalmology Department

    DIAGNOS inc. (“DIAGNOS” or the “Company”) (TSX Venture Exchange: ADK) (DGNOF), a leader in the early detection of serious health issues thanks to its artificial intelligence technology, FLAIRE, adds a second site to screen patients in the ophthalmology department at the Centre Hospitalier de l’Université de Montréal (CHUM) for the automated diabetic retinopathy screening clinic assisted by AI (Artificial Intelligence). To further its collaboration with the ophthalmology department, DIAGNOS is installing a second site in that department. The objective is to continue to improve the screening process with patients posing more challenging conditions. This proprietary service is only available via our CARA telehealth platform (Computer Assisted Retina Analysis).

  • GlobeNewswire

    DIAGNOS Completes Redemption of Convertible Debt

    DIAGNOS Inc. (“DIAGNOS”, “the Corporation” or “we””) (TSX Venture: ADK), (DGNOD), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), is pleased to announce that it has completed the redemption of the outstanding 10% secured convertible debentures and part (85%) of the outstanding unsecured convertible notes (together, the “Convertible Debt”) by issuing 18,651,547 common shares of the Corporation (each, a “Share”) at the deemed price of $0.35 per Share, in payment of the principal amount of the Convertible Debt of $5,790,000 and the unpaid and accrued interest of $738,047, for an aggregate amount of $6,528,047. The intention of the Corporation to proceed with the redemption of the Convertible debt was previously disclosed in the press release dated April 30, 2019.

  • GlobeNewswire

    DIAGNOS Announces Symbol Change on the OTCQB: DGNOD

    BROSSARD, Quebec, May 08, 2019 -- Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK), (OTCQB: DGNOD), a leader in early detection of critical health issues.

  • GlobeNewswire

    DIAGNOS Announces Saudi FDA Filing for its CARA AI Platform

    DIAGNOS Inc. (“DIAGNOS”, “the Corporation” or “we”) (TSX Venture: ADK) (DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today that it has started the marketing authorization filing process with the Saudi Food and Drug Authority (SFDA) for its CARA proprietary tool comprised of a telemedicine platform combined with automated detection algorithms based on Artificial Intelligence. The telemedicine platform as well as the associated algorithms will be part of the submission to the SFDA for approval.

  • GlobeNewswire

    DIAGNOS Joins Forces with a Cannabis-Based Medicinal Products Distributor

    Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK), (DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), is pleased to announce that it has signed a one-year agreement (the “Agreement”) with Organic Medical Growth OMG3 Inc. (“OMG”) which will enable DIAGNOS to have access to more than 7,800 points of sale across Colombia. Under the Agreement, DIAGNOS’ AI diabetic retinopathy screening platform CARA will be available for trial in five pharmacies across Colombia.

  • GlobeNewswire

    DIAGNOS Redeems Convertible Debt

    BROSSARD, Québec, April 30, 2019 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS”, “the Corporation” or “we””) (TSX Venture: ADK), (DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces that it will redeem on May 15, 2019, the outstanding convertible debentures and part of the outstanding notes, in the aggregate principal amount of $5,790,000 plus any unpaid and accrued interest owing. As of today, the interest owed is $697,670, for a total of $6,487,670, and in payment thereof, 18,536,119 common shares (each, a “Share”) of the Corporation will be issued at the deemed price of $0.35 per Share. An additional number of Shares representing the interest accrued from of May 1, 2019 to May 14, 2019 will be issued on May 15, 2019, at $0.35 per Share or at such price as may be acceptable by the TSX Venture Exchange.

  • GlobeNewswire

    DIAGNOS Successfully Completes ISO 13485:2016 MDSAP Audit

    DIAGNOS Inc. (“DIAGNOS”, “the Corporation” or “we”) (TSX Venture: ADK) (DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today that its quality management system continues to fully comply with the requirements of ISO 13485:2016 - Medical devices quality standard. As part of the requirements for the commercialization of our flagship product CARA from Health Canada, the Food and Drug Agency in the US and CE in Europe, DIAGNOS must undergo thorough statutory annual quality compliance audits, such as the Medical Device Single Audit Program (MDSAP).

  • GlobeNewswire

    DIAGNOS Will Supply Its Artificial Intelligence Technology to the First Hypertensive Retina Screening Clinic in Saudi Arabia.

    DIAGNOS Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK), (DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today it will supply its Artificial Intelligence technology to the first Hypertensive Retina Screening Clinic in Saudi Arabia with Kanhoor Medical Inc. (“Kanhoor”). “We are delighted to open our first screening clinic for HBP in collaboration with DIAGNOS”, said the President of Kanhoor, Mr. Rashid AlMugait.

  • GlobeNewswire

    DIAGNOS Announces Approval of Corporate Reorganization

    BROSSARD, Quebec, April 10, 2019 -- DIAGNOS Inc. (“DIAGNOS”, “the Corporation” or “we””) (TSX Venture: ADK), (OTCQB: DGNOF), a leader in early detection of critical health.

  • GlobeNewswire

    DIAGNOS Announces New Contract with Government in Bangladesh Through its Partner Eyes for All

    DIAGNOS Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK), (DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today the opening of the first eye screening diabetic clinic with a world leading global health research institute in Dhaka, Bangladesh. The International Diabetes Federation (“IDF”) estimates that by 2030, Bangladesh would emerge as one of the countries with the largest number of people with type 2 diabetes.

  • GlobeNewswire

    DIAGNOS Announces an Update to the News Release Issued Earlier Today

    DIAGNOS Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK), (DGNOF), a leader in early detection of critical health issues through the use of its proprietary FLAIRE platform based on Artificial Intelligence (AI), announces an update to provide more details with regards to the news release issued earlier today for the signing of a memorandum of understanding between one hospital in the US (the “Partner”) and DIAGNOS. DIAGNOS expects to sign a definitive agreement with Partner within 45 days from the date of this news release.

  • GlobeNewswire

    DIAGNOS Announces Memorandum of Understanding with one of the 5 largest hospitals in the US for the final development of its CARDIO application

    DIAGNOS Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK), (DGNOF), a leader in early detection of critical health issues through the use of its proprietary FLAIRE platform based on Artificial Intelligence (AI), announces today the signing of a memorandum of understanding to establish a framework between one hospital in the US and DIAGNOS. Under the terms of a mutual non-disclosure agreement, the name of the hospital can’t be disclosed.  The hospital is engaged and specializes in the medical field of stroke and related cardiological issues.  The hospital has one of the largest databases in the world for stroke related patients. DIAGNOS will utilize this database to finalize the development and validation for CARDIO.

  • CNW Group

    Leonite Captal LLC Issues Open Letter to Debenture Holders of Diagnos Inc.

    TORONTO , March 26, 2019 /CNW/ - Leonite Capital LLC, today issued the following letter to the holders of 10% Senior Convertible Secured Debentures (the "Debentures") of Diagnos Inc. (TSX Venture: ADK), (DGNOF) (the "Corporation" or "Diagnos") in connection with the proposed restructuring set forth in Diagnos' press release dated March 11, 2019 . Leonite Capital LLC, as a holder of the 10% Senior Convertible Secured Debentures (the "Debentures") of Diagnos Inc. (the "Corporation") strongly opposes the proposed corporate reorganization announced by the Corporation on March 11, 2019 and recommends that holders of Debentures vote AGAINST such proposal at the upcoming meeting of holders of Debentures.

  • GlobeNewswire

    DIAGNOS Announces New Agreement in the United Arab Emirates with one of the Largest Pharmaceutical Companies in the World

    DIAGNOS Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK), (DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today the signing of a significant renewal contract in the United Arab Emirates consisting of a turnkey one-year screening contract for 2 CARA platform services. During the period covered by the agreement, DIAGNOS estimates that an additional 5,000 patients will be screened in UAE using its CARA platform.

  • GlobeNewswire

    DIAGNOS Announces Corporate Reorganization

    DIAGNOS Inc. (“DIAGNOS”, “the Corporation” or “we””) (TSX Venture: ADK), (DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces that it has taken steps to reorganize its debt and capital structure to allow it to efficiently allocate its resources and pursue the growth of the business. As such, Diagnos has put in place a special reorganization team to cover all strategic, legal, organizational and financial aspects of the proposed reorganization.

  • GlobeNewswire

    DIAGNOS Welcomes Dr. Jean-Francois Yale to the Board of Directors

    Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK) (DGNOF) a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), is pleased to announce the appointment of Dr. Jean-Francois Yale to its board of directors. Dr. Yale is an endocrinologist, currently professor of medicine at the McGill University Department of Medicine. Dr. Yale chaired the Clinical and Scientific Section of the Canadian Diabetes Association from 1992-1994 as well as the Expert Committee that published the 2001 Clinical Practice Guidelines for the Prevention and Management of Diabetes.

  • GlobeNewswire

    DIAGNOS Announces Closing of Private Placement

    BROSSARD, Quebec, Dec. 12, 2018 -- DIAGNOS Inc. (“DIAGNOS”, the “Corporation” or the “Issuer”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health.

  • GlobeNewswire

    DIAGNOS is announcing a collaboration with ÉTS on Automated detection and grading of Diabetic Retinopathy using Deep Convolutional Neural Networks, (CNN) a new generation of Deep Learning Technique  

    BROSSARD, Quebec, Dec. 04, 2018 -- Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture:ADK), (OTCQB: DGNOF), a leader in early detection of critical health issues.